SCHEMBL507362

SCHEMBL507362

NC1COc2ccccc21

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LTB4R Q15722 1/20 0.43
LTB4R2 Q9NPC1 1/20 0.43
NISCH Q9Y2I1 2/20 0.40
TRPM8 Q7Z2W7 1/20 0.40
DRD2 P14416 1/20 0.40
DRD3 P35462 1/20 0.40
CYP2D6 P10635 2/20 0.40
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.39
CYP19A1 P11511 1/20 0.39
ITGB2 P05107 1/20 0.39
ICAM1 P05362 1/20 0.39
ITGAL P20701 1/20 0.39
DPP4 P27487 1/20 0.37
CA2 P00918 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30888065 1.00 LTB4R (0.43) LTB4RLTB4R2NISCHTRPM8DRD2
Hydrochloric Acid SCHEMBL1163031 0.98 LTB4R (0.42) LTB4RLTB4R2NISCHTRPM8DRD2
Hydrochloric Acid SCHEMBL30888110 0.98 LTB4R (0.42) LTB4RLTB4R2NISCHTRPM8DRD2
Trifluoroacetic Acid SCHEMBL14916303 0.83 TRPM8 (0.43) LTB4RLTB4R2TRPM8
SCHEMBL7347250 0.78 KDM1A (0.35) LTB4RLTB4R2NISCHSLC6A2ABCG2
SCHEMBL29764040 0.78 ITGB2 (0.46) SLC6A2SLC6A4ABCG2ITGB2ICAM1
SCHEMBL193981 0.78 ITGB2 (0.46) SLC6A2SLC6A4ABCG2ITGB2ICAM1
SCHEMBL29858755 0.78 ITGB2 (0.46) SLC6A2SLC6A4ABCG2ITGB2ICAM1
SCHEMBL30563663 0.78 ITGB2 (0.46) SLC6A2SLC6A4ABCG2ITGB2ICAM1
SCHEMBL2627039 0.78 ITGB2 (0.46) SLC6A2SLC6A4ABCG2ITGB2ICAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119613362-A Preparation method of 3-amino-2, 3-dihydrobenzofuran compound 江西师范大学 2025-03-14 CN claimed
US-20180099936-A1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A AbbVie Deutschland GmbH & Co. KG (DE) 2018-04-12 US claimed
US-9856220-B2 Inhibitor compounds of phosphodiesterase type 10A AbbVie Deutschland GmbH & Co. KG (DE) 2018-01-02 US claimed
EP-2780324-B1 HETEROCYCLIC CARBOXAMIDES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE TYPE 10A ABBVIE DEUTSCHLAND (DE) 2017-05-17 EP claimed
US-20160318871-A1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A ABBVIE INC. 2016-11-03 US claimed
EP-2780324-A1 HETEROCYCLIC CARBOXAMIDES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE TYPE 10A Abbvie Deutschland GmbH & Co. KG (DE) 2014-09-24 EP claimed
WO-2013068489-A1 HETEROCYCLIC CARBOXAMIDES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE TYPE 10A ABBOTT GMBH & CO. KG (DE) 2013-05-16 WO claimed
US-20130116229-A1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A ABBVIE INC. (US) 2013-05-09 US claimed
EP-1136477-B1 BENZOFURAN DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2004-03-10 EP claimed
CN-122070134-A Use of PRMT5 inhibitors in the treatment of tumors or cancers 上海湃隆生物科技有限公司 2026-05-19 CN disclosed
WO-2025217330-A1 CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2025-10-16 WO disclosed
EP-4010330-B1 QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS HIRUNDO BIOSCIENCES (BE) 2025-10-01 EP disclosed
EP-4612131-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2025-09-10 EP disclosed
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 EP disclosed
CN-1154962-A Amidine derivative and platelet agglutination inhibitor containing said amidine derivative MITSUI TOATSU CHEMICALS (JP) 1997-07-23 CN disclosed
CN-1093706-A Crystalline salt and the preparation and the purposes of the amino coumaran derivative of optically-active TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1994-10-19 CN disclosed
CN-1093706-A Crystalline salt and the preparation and the purposes of the amino coumaran derivative of optically-active TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1994-10-19 CN disclosed
CN-1071165-A Aminocoumaran derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1993-04-21 CN disclosed
CN-1071165-A Aminocoumaran derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1993-04-21 CN disclosed
CN-1071165-A Aminocoumaran derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1993-04-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318871-A1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A PDE3A, PDE5A, PDE3B LTB4R 623/4885LTB4R2 472/4885NISCH 2706/4885
US-20130116229-A1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A PDE7A, PDE5A, PDE2A LTB4R 3323/4885LTB4R2 3055/4885NISCH 1713/4885
US-20180099936-A1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A PDE3A, PDE5A, PDE3B LTB4R 640/4885LTB4R2 483/4885NISCH 2699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.